SANOFI-AVENTIS (EPA:SAN) | WebDisclosure

Basculer en Français

9479	Companies
185510	Keywords
117899	Articles
99364	Press releases

Home
Companies
SANOFI-AVENTIS

PRESS RELEASE

published on 06/12/2024 at 20:19, 1 year 5 months ago

Sanofi: Informations relatives au nombre de droits de vote et d'actions - Mai 2024
Analyse des droits de vote et d'actions de Sanofi selon les réglementations en vigueur

Autorité Des Marchés Financiers Droits De Vote Actions Règlement Général Sanofi
PRESS RELEASE

published on 06/12/2024 at 20:19, 1 year 5 months ago

Sanofi: Information concerning the total number of voting rights and shares – May 2024
Sanofi discloses total number of voting rights and shares as per French commercial code and stock market authority regulations. Details available on Sanofi's website

Voting Rights French Commercial Code Shares Sanofi Stock Market Authority
BRIEF

published on 06/03/2024 at 22:20, 1 year 6 months ago

Étude de phase III : Sarclisa améliore la survie sans progression des patients atteints de myélome multiple

Myélome Multiple Sarclisa ASCO Étude De Phase III Survie Sans Progression
BRIEF

published on 06/03/2024 at 22:20, 1 year 6 months ago

Phase III study: Sarclisa improves progression-free survival of patients with multiple myeloma

Multiple Myeloma Sarclisa ASCO Phase III Study Progression-free Survival
PRESS RELEASE

published on 06/03/2024 at 22:15, 1 year 6 months ago

Communiqué de presse : ASCO : Sarclisa, en association avec un protocole VRd, est le premier anti-CD38 permettant d’améliorer significativement la survie sans progression des patients […]
Sarclisa associé à VRd améliore la survie sans progression chez les patients atteints de myélome multiple non éligibles à une transplantation, selon l'étude IMROZ publiée dans NEJM

Myélome Multiple Sarclisa VRd Patients Non Éligibles Étude IMROZ
PRESS RELEASE

published on 06/03/2024 at 22:15, 1 year 6 months ago

Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3
Sarclisa in combo with VRd significantly enhances progression-free survival in newly diagnosed transplant-ineligible multiple myeloma in phase 3 study at ASCO. Full data published in NEJM

Multiple Myeloma Phase 3 Sarclisa Progression-free Survival VRd
BRIEF

published on 05/31/2024 at 12:05, 1 year 6 months ago

Sanofi Launches 2024 Global Employee Stock Purchase Plan

Financial Investment Sanofi Employee Stock Purchase Plan Action 2024 Global Participation
BRIEF

published on 05/31/2024 at 12:05, 1 year 6 months ago

Sanofi lance un plan mondial d'achat d'actions pour les salariés en 2024

Investissement Financier Sanofi Plan D'achat D'actions Pour Les Salariés Actions 2024 Participation Mondiale
PRESS RELEASE

published on 05/31/2024 at 12:00, 1 year 6 months ago

Press Release: Sanofi launches 2024 global Employee Stock Purchase Plan
Sanofi launches 2024 global Employee Stock Purchase Plan, Action 2024, offering discounted shares to 80,000 employees in 56 countries. CEO Paul Hudson affirms commitment to employee participation and company growth

Company Growth Sanofi Employee Stock Purchase Plan Action 2024 Employee Shareholders
PRESS RELEASE

published on 05/31/2024 at 12:00, 1 year 6 months ago

Communiqué de presse : Sanofi lance son plan mondial 2024 d’actionnariat salarié
Sanofi lance son plan mondial 2024 d'actionnariat salarié, ouvert à 80 000 salariés dans 56 pays, offrant actions à 72,87 € avec décote de 20%. Conditions et dates clés précisées pour la souscription

Actionnariat Salarié Souscription Sanofi Plan 2024 Entreprise De Santé

Accesswire

Published on 12/05/2025 at 17:15, 52 minutes ago

TRX GOLD Attending the 3rd Annual DealFlow Discovery Conference
Published on 12/05/2025 at 17:00, 1 hour 7 minutes ago

Three Trillion-Dollar Frontiers, One Technology: How SMX Is Everywhere at Once
Published on 12/05/2025 at 16:00, 2 hours 7 minutes ago

SMX Didn't Change Its Story; The World Finally Connected the Dots
Published on 12/05/2025 at 15:45, 2 hours 22 minutes ago

Critical Elements announce la clôture d'un placement privé de 7,0 $ million ca par voie de prise ferme
Published on 12/05/2025 at 15:45, 2 hours 22 minutes ago

Critical Elements Announces Closing of C$7.0 Million Bought Deal Life Private Placement

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 17:51, 15 minutes ago

Issue of Equity
Published on 12/05/2025 at 17:46, 20 minutes ago

Booster Precision Components Holding GmbH announces the successful completion of its Written Procedure to amend and waive certain terms under the terms and conditions of the Bonds
Published on 12/05/2025 at 17:00, 1 hour 6 minutes ago

EQS-Adhoc: The NAGA Group AG adjusts guidance for financial year 2025 following continued low volatility and weaker year-end performance
Published on 12/05/2025 at 16:25, 1 hour 41 minutes ago

4YFN26 Awards: Meet the Top 20 startups building the future
Published on 12/05/2025 at 16:10, 1 hour 56 minutes ago

Reorganization of the Eckert & Ziegler Executive Board

Les Echos

Published on 12/05/2025 at 17:18, 48 minutes ago

La vidéo de la réunion de présentation des résultats 2024-2025 du 5 décembre 2025 est disponible
Published on 12/05/2025 at 17:18, 48 minutes ago

The video of the 2024-2025 results presentation meeting on December 5, 2025, is available
Published on 12/05/2025 at 15:10, 2 hours 56 minutes ago

Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 15:10, 2 hours 56 minutes ago

Mersen : nombre d'actions et de droits de vote au 30 novembre 2025
Published on 12/05/2025 at 13:58, 4 hours 8 minutes ago

RELATIF A LA MISE A DISPOSITION DU PUBLIC DE LA NOTE D'INFORMATION ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES, NOTAMMENT JURIDIQUES, FINANCIERES ET COMPTABLES DE LEGRAND FRANCE

View all LES ECHOS COMFI WIRE